369.3 ð¥ å §ç§å°ç§èåç
369.3.1 Mechanistic Deep Dive
369.3.1.1 Anterior Horn Cell Diseases
- ALS (sporadic + familial)
- SMA (5q SMN1)
- Poliomyelitis
- PMA, PLS (motor neuron variants)
- Post-polio syndrome
- Kennedy disease (X-linked bulbospinal)
369.3.2 Recent Trials & Updates
369.3.2.1 MG Treatment (Detailed in Ch383)
- Efgartigimod (Vyvgart) â FcRn inhibitor, FDA 2021
- Rozanolixizumab (Rystiggo) â FcRn, FDA 2023
- Zilucoplan (Zilbrysq) â complement C5, FDA 2023
- Ravulizumab (Ultomiris) â complement C5, FDA 2022 for MG
- Eculizumab (Soliris) â complement C5
369.3.2.2 ALS Treatment (Detailed in Ch383)
- Tofersen (Qalsody) â SOD1 antisense, FDA 2023
- Riluzole
- Edaravone
- AMX0035 (withdrawn 2024)
369.3.3 High-Yield Specialist Points
369.3.3.1 Approach to Pure Motor Weakness
- UMN: stroke, MS, MND
- LMN: motor neuropathy (multifocal motor neuropathy), motor neuron disease
- NMJ: MG, LEMS
- Muscle: myopathy
369.3.3.2 Pseudobulbar Affect
- UMN bulbar
- Pathological laughing/crying
- ALS, stroke, MS
- Treatment: dextromethorphan-quinidine (Nuedexta), SSRI
369.3.3.3 Acute Flaccid Paralysis (AFP) Differential
- GBS (most common)
- Poliomyelitis (rare)
- Enterovirus 71, EV-D68 (acute flaccid myelitis)
- Botulism
- Periodic paralysis
- Tick paralysis
- Transverse myelitis
- Spinal cord trauma
369.3.3.4 Acute Flaccid Myelitis (AFM)
- Enterovirus D68, A71
- Pediatric
- Acute asymmetric flaccid weakness
- Resembles polio
- Limited treatment
369.3.4 Pearls
- Localize before etiology
- UMN vs LMN distinction critical
- EMG/NCS key for localization
- CK elevated in myopathy, rhabdo
- GBS: ascending, areflexia, after URI/GI â IVIG/PE
- MG: fatigable, ocular/bulbar â AChR Abs, pyridostigmine + IS
- LEMS: proximal improves with use â VGCC Abs, often SCLC
- ALS: combined UMN + LMN, no sensory
- Polymyositis/DM: proximal + â CK + steroids
- AFM: pediatric enterovirus